Advertisement

Picture [iito] Männer Ballett 650x80px
Document › Details

Gain Therapeutics SA. (9/12/19). "Press Release: Gain Therapeutics SA Announces Jeffrey Riley to join its Board of Directors". Lugano.

Organisations Organisation GT Gain Therapeutics S.A. (Gain Therapeutics)
  Group Gain Therapeutics (Group)
  Organisation 2 Pfizer (Group)
Products Product SEE-Tx platform (Site-directed Enzyme Enhancement Therapy platform
  Product 2 drug development
Persons Person Riley, Jeffrey (Gain Therapeutics 201909– Independent Board Director formerly SKB + Pfizer + Queensland Biocapital Fund)
  Person 2 Islam, Khalid (Gentium 200912– CEO before Arpida 199907–200805 CEO)
     


Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in CNS diseases, today announced that Mr. Jeffrey Riley joined Gain Therapeutics as Independent Board Member.

Mr. Riley has more than 25 years of experience in the biotechnology and pharmaceutical industries, during which he has negotiated numerous worldwide strategic corporate alliances, established joint ventures and assisted in venture financings to support product development. He has raised over $1.5B in equity and debt instruments. He has worked for big pharma (SmithKline Beecham and Pfizer), venture capital (Queensland Biocapital Fund / QIC) and numerous biotechnology companies in his capacity of business development and general management.

“We are delighted to have Jeff join us as an independent board member,” said Dr. Khalid Islam, Chairman of the Board of Gain Therapeutics SA. “Jeff’s perspective, based on his distinguished career and leadership roles in R&D organizations and his transactional expertise will be very valuable to the board as the company seeks to execute on its global product discovery and development strategy."

“I am delighted to join Gain Therapeutics and support its endeavors to bring to patients brain penetrant small molecule able to regulate misfolded enzymes involved in rare pediatric diseases and in neurodegenerative disease for which high unmet medical needs still exist.” Said Mr. Jeffrey Riley, Independent Board member of Gain Therapeutics.


About Gain Therapeutics SA

Gain Therapeutics SA is a Swiss biotech company specializing in the discovery of new drugs for rare and CNS diseases. The company targets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs. Gain Therapeutics SA is developing a new class of compounds: structurally targeted allosteric regulators, identified through its pioneering proprietary platform – SEE-Tx.

https://www.gaintherapeutics.com/


Contacts

For Gain Therapeutics SA
Dr. Manolo Bellotto, General Manager
+41 91 921 1524
mbellotto@gaintherapeutics.com

   
Record changed: 2020-12-28

Advertisement

Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Gain Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Made Without Love 650x80px




» top